We have developed a solid phase direct radioimmunoassay (RIA) for urinary throm-boxane B
2. We raised anti-TXB
2 rabbit antiserum, using TXB
2 conjugated to throglobulin as the immunogen. The antiserum which was diluted 1.5×10
5 times was used in a solution phase RIA system. ID
50 and minimum detectable dose (ID
10) were 9 and 1.5 pg/tube, respectively. Dissociation constant (Kd) was 4.1×10
-11 M. The crossreactivities were 0.1% with PGF
2α, 0.06% with PGD
2 and less than 0.01% with other PGs. The antiserum was coupled to polyacrylamide beads to obtain the solid phase antiserum. In the solid phase RIA system, ID
50 and ID
10 were 11 and 2 pg/tube, respectively. Kd was 2.9×10
-10M. Recovery rates of authentic TXB2 added to a urine sample ranged from 97 to 125% at concentrations of 2 to 125 pg/tube in the direct assay system. The blank value was less than 1 pg/tube. Coefficients of variation for intra and interassay variation were 6.1 and 7.2%, respectively. The values measured by the solid phase direct RIA significantly correlated with those by the solution phase RIA, which required extraction of TXB
2 from urine samples. Utilizing the solid phase direct RIA, urinary excretion rates of TXB
2 were measured in 32 patients with biopsy-proven chronic primary glomerulonephritis. The excretion rates ranged from 73 to 568 pg/min. There was not a definite relationship between the urinary excretion rates of TXB
2 and the histological types of the glomerulonephritis. The direct assay system for urinary TXB
2 that we have developed is simple, time-saving and highly sensitive. Thus, the assay system seems to be useful for clinical applications.
抄録全体を表示